Tara M. Robinson

Medical Director, Clinical Science
BioMarin Pharmaceutical Inc., Novato, CA, USA

Presentation(s):

• LB 01.3 - Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, July 10, 2022
  3:15 PM – 3:30 PM

• OC 21.2 - Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• OC 21.5 - Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• PB0210 - Blood Biodistribution and Vector Shedding of Valoctocogene Roxaparvovec in People with Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM